Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
FDA OKs Sale of Combo Drug JANUMET® XR
The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC.
Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that reduces the production of glucagon, a pancreatic hormone that increases blood glucose levels. Metformin, an established and widely used drug for treating type 2, works by decreasing the liver's production of glucose.
Merck's randomized, double-blind, placebo-controlled study of JAMUMET XR in 1,091 type 2 patients showed that over a 24-week period, the sitagliptin-metformin combination helped patients achieve a 2.1% reduction in A1C levels, down from a mean baseline of 8.8%.
JANUMET XR's once-daily regimen makes it easier for type 2 patients to follow their therapy routine. Dosage of the drug may vary according to whether patients are taking other drugs, such as insulin or sulfonylureas. JANUMET XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Categories: Blood Glucose Levels, Diabetes, Diabetes, Diabetic Ketoacidosis, DPP-4 Inhibitor, Extended-Release Metformin, Glucagon, Janumet, JANUMET XR, Januvia, Juvisync, Merck, Metformin, Pancreatic Hormone, Sitagliptin, Type 1 Issues, Type 2 Diabetes, Type 2 Issues
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...